Ivermectin ineffective in large study of treatment among patients with Covid-19
On Mar. 31, 2022, researchers in Brazil reported that a study of COVID-19 patients at 12 clinics that…
Novavax submitted request to expand conditional Marketing Authorization of COVID-19 vaccine in the EU to adolescents
On Mar. 31, 2022, Novavax announced submission of its request to expand the conditional marketing authorization (CMA) of…
NIH began clinical trial evaluating second COVID-19 booster shots in adults
On Mar. 31, 2022, the National Institutes of Health (NIH) and Moderna announced a phase 2 clinical trial…
Sorrento reported FDA clearance for phase 2/3 study for Abivertinib in treatment of pospitalized patients with severe pneumonia due to COVID-19
On Mar. 31, 2022, Sorrento Therapeutics announced that the FDA had given clearance to commence the Phase 3…
Lucira’s COVID-19 & flu at-home molecular test showed Positive clinical trial results
On Mar. 30, 2022, Lucira Health announced that preliminary clinical trial results for its candidate COVID-19 & Flu…
CureVac and GSK started clinical development of second-generation COVID-19 vaccine Candidate, CV2CoV
On Mar. 30, 2022, CureVac announced that the first participant was dosed in a Phase 1 study of…
Moderna received FDA approval for EUA of 2nd booster dose of its COVID-19 vaccine, mRNA-1273
On Mar. 29, 2022, Moderna announced that it had received approval from the U.S. Food and Drug Administration…
Pfizer and BioNTech received expanded U.S. EUA for additional COVID-19 vaccine booster in individuals Aged 50 Years and older
On Mar. 29, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had expanded…
Moderna finalized strategic partnership with Australian government
On Mar. 23, 2022, Moderna announced the finalization of a strategic partnership with the Australian Federal Government to…
Moderna announced COVID-19 vaccine phase 2/3 study in children 6 months to Under 6 years met Its primary endpoint
On Mar. 23, 2022, Moderna announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna…
Quest Diagnostics granted CDC contract to support COVID-19 infection and vaccination seroprevalence research
On Mar. 23, 2022, Quest Diagnostics announced that it had been granted a contract by the Centers for…
Pfizer supplied UNICEF 4 million treatment courses of novel COVID-19 oral treatment for low- and middle-Income countries
On Mar. 22, 2022, Pfizer announced an agreement with UNICEF to supply up to 4 million treatment courses…
Windtree announced results from phase 2 study of lucinactant for COVID-19 associated ARDS and Lung Injury
On Mar. 22, 2022, Windtree Therapeutics announced results from its Phase 2 study of lucinactant (KL4 surfactant) for…
Moderna announced new supply agreement for 2023 with Switzerland for seven million doses of COVID-19 booster vaccine
On Mar. 21, 2022, Moderna announced announced a supply agreement with the Swiss Federal Government for seven million…
Health Canada authorized Moderna’s COVID-19 vaccine in children (6-11 Years)
On Mar. 17, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…
Eiger’s single-dose Peginterferon Lambda for COVID-19 reduced risk of hospitalization or ER visits by 50% in vaccinated population
On Mar. 17, 2022, Eiger BioPharmaceuticals announced that Peginterferon Lambda (Lambda) significantly reduced the risk of COVID-19-related hospitalizations…
Soligenix COVID-19 vaccine, CiVax, boosted neutralizing activity against SARS-CoV-2, including Delta and Omicron
On Mar. 17, 2022, Soligenix announced the results of a booster vaccination study using CiVax (heat stable COVID-19…
Moderna submited amendment to EUA for an additional booster dose of its COVID-19 vaccine in the U.S.
On Mar. 17, 2022, Moderna announced that it had submitted a request to the U.S. Food and Drug…
Moderna to supply Japan with additional 70 million doses of COVID-19 booster vaccine
On Mar. 16, 2022, Moderna announced an agreement with the Ministry of Health, Labour and Welfare of Japan…
Pfizer and BioNTech submitted for U.S. EUA of additional booster dose of COVID-19 vaccine for older adults
On Mar. 15, 2022, Pfizer and BioNTech announced the companies had submitted an application to the U.S. Food…
COVID-19 | HIV | Life Science News | NIH | Non-Profit Research | Vaccine
NIH launched clinical trial of three mRNA HIV vaccines
On Mar. 14, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced they had…
CDC reported effectiveness of 2-Dose BNT162b2 mRNA vaccine in preventing SARS-CoV-2 infection among children
On Mar. 11, 2022, the BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine was recommended by CDCﾒs Advisory Committee on Immunization…
Moderna announced first participant dosed in phase 2 study of Omicron-specific bivalent booster candidate
On Mar. 10, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
IHME reported three times as many deaths worldwide due to COVID-19 than official reports suggested
On Mar. 10, 2022, the Institute for Health Metrics and Evaluation (IHME) reported that more than three times…
City of Hope COVID-19 vaccine showed effectiveness in phase 1 trial
On Mar. 10, 2022, the City of Hope announced that its COVID-19 investigational vaccine licensed to GeoVax Labs…
Pfizer initiated phase 2/3 study of novel COVID-19 oral treatment in pediatric participants
On Mar. 9, 2022, Pfizer announced that it had initiated a Phase 2/3 study, EPIC-PEDS (Evaluation of ProteaseInhibition…
NIH launched trial to study allergic reactions to COVID-19 mRNA vaccine
On Mar. 9, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced a clinical…
Innovation Pharmaceuticals reported additional findings from Brilacidin phase 2 COVID-19 tial results
On Mar. 7, 2022, Innovation Pharma announced the Company was conducting full data analysis of the Phase 2…
CDC reported disparities in COVID-19 vaccination coverage between urban and rural counties
On Mar. 4, 2022, the CDC reported that COVID-19 vaccination coverage with the first dose of the primary…
WHO and MPP welcomed NIHﾒs offer of COVID-19 health technologies to C-TAP
On Mar. 3, 2022, the WHO and the Medicines Patent Pool (MPP) jointly welcomed the announcement that the…